Table 6.
Longitudinal studies of stains and risk of non‐Hodgkin's lymphoma (NHL)
| Ref | Study type | Sample size | Exposure | Outcome | HR, 95% CI |
|---|---|---|---|---|---|
| Jacobs 9 | Cohort | Cases: 1005 Pop: 133, 255 |
Current < or > 5 years | NHL DLCL |
0.74 (0.62–0.86) 0.68 (0.46–1.00) |
| Desai | Cohort |
Cases: 712 Pop: 161,563 |
Current < or > 3 years and time dependent |
NHL Lipophilic statins DLCL |
0.81 (0.66–0.99) 0.82 (0.66–1.03) 0.61 (0.41–0.91) |
| Vingradova 10 | 1 Nested Case–Control |
Cases of heme cancers: 7185 Controls: 29,162 |
Statin yes vs. no | Hematologic Malignancies (including leukemia, myeloma, and NHL) | 0.61 (0.41–0.89) |
| Epilymph study 11 | Case–Control |
Cases‐2362 Controls: 2206 |
Ever use of statins | NHL (B, T, and NK) | 0.61 (0.41–0.89) |